Aurobindo Pharma’s subsidiary, TheraNym Biologics, is strengthening its collaboration with MSD by announcing a major expansion in biologics manufacturing. The company plans to invest between $150 million and $175 million to establish a new greenfield facility, marking a significant step in its global biologics strategy.
Greenfield Facility to Boost Manufacturing Capacity
As part of the expansion, TheraNym Biologics will build a 60,000-litre mammalian bioreactor facility (Unit 2). The development builds on the agreement signed in May 2024 and is aimed at significantly enhancing large-scale biologics production capacity. The new facility will be equipped with advanced downstream purification systems, enabling the efficient production of high-quality biologic drug substances for both domestic and international markets.
Strategic Investment Strengthens Contract Manufacturing Role
To support the initiative, TheraNym Biologics will invest approximately $150–$175 million in the new unit. Under the agreement, the company will not only construct and operate the facility but also manufacture and supply biologic products to MSD. As a result, the move significantly strengthens Aurobindo’s position as a contract manufacturing organization (CMO) in the fast-growing biologics segment.
Meeting Rising Global Demand for Biologics
The expansion comes at a time when global demand for large-scale mammalian cell culture capacity is increasing rapidly. Therefore, this investment enables Aurobindo Pharma to capture emerging opportunities in biologics manufacturing while ensuring scalability and operational efficiency. In addition, the facility will enhance supply capabilities for global markets, positioning the company as a reliable partner for high-volume biologics production.
Reinforcing Long-Term Partnership with MSD
By deepening its collaboration with MSD, Aurobindo Pharma continues to strengthen its long-term strategic relationship with a leading global pharmaceutical company. As reported by indianpharmapost.com, the expansion reflects Aurobindo’s focused push into biologics, combining advanced manufacturing capabilities, strategic investments, and global partnerships to drive future growth in the biopharma sector.
